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InTrODUcTIOn
For more than half a century, cancer metabolism studies 
have focused on cell proliferation through anabolic pathways. 
Warburg described the major role of aerobic glycolysis in pro-
liferating cancer cells converting glucose to lactate, generat-
ing biomass such as amino acids, fatty acid, and nucleotides 
(Warburg, 1956; Vander Heiden et al., 2010). Unlike in vitro, 
cancer cells in vivo are repeatedly subjected to resource-
limited microenvironments of nutrition depletion, hypoxia and 
acidosis which induce in the cells a more quiescent, catabolic 
slow-life (slow proliferating cancer cells) stage which enables 
survival under metabolic stress (Ward and Thompson, 2012; 
Aktipis et al., 2013). Because the metabolic stress inevitably 
induces ROS-mediated oxidative stress, even under hypoxic 
condition (Chandel et al., 1997, Kang et al., 2015) nicotin-
amide adenine dinucleotide phosphate (NADPH) homeosta-
sis is critical for cancer cell survival under starved microen-
vironment. It should be noted that current standard cancer 
therapeutics, such as chemotherapy and radiotherapy, also 
significantly induces oxidative stress in cancer cells, and an-
tioxidant capacity provides therapeutic resistance in cancer 
cells (Ramanathan et al., 2005; Diehn et al., 2009; Decrock et 
al., 2017). While little is known about the metabolic pathways 
promoting NADPH homeostasis in cancer, emerging evidence 
reveals an important molecular network regulating metabolic 
flux into the pentose phosphate pathway for NADPH genera-
tion.
OvervIew: PenTOse PhOsPhaTe PaThway 
(PPP) anD glycOlysIs
Non-dividing normal differentiated cells mainly depend on 
mitochondrial oxidative phosphorylation to generate ATP (ad-
enosine 5’-triphosphate). However, most human cancer cells 
metabolize the glucose through glycolysis (known as War-
burg effect, for review glycolysis, see Vander Heiden et al., 
2009), producing pyruvate and lactate as final metabolites in 
cells (Fig. 1). Although the glycolysis is inefficient in produc-
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ing ATP, proliferating cancer cells under nourished condition 
utilize glucose in biomass production (such as amino acids, 
nucleotides, and fatty acids) to support new cells. Because the 
biologic aspects of glycolysis in proliferating fast-life of cancer 
cells are well-known, we mainly focused on the importance 
and regulatory network of PPP in supporting slow-life of can-
cer cells.
The PPP (also known as the phosphogluconate pathway 
or the hexose monophosphate shunt) branched form glycoly-
sis at the first committed step of glucose-6-phosphate (G-6-P) 
(Fig. 1). The PPP promotes the oxidative decarboxylation of 
G-6-P (oxidative PPP branch), yielding ribulose-5-phosphate 
(Ru-5-P). The Ru-5-P is isomerized into ribose-5-phosphate 
(R-5-P), which either serves as a nucleotide precursor or is 
metabolized through the non-oxidative PPP branch to produce 
fructose-6-phosphate (F-6-P) and glyceraldehyde-3-phos-
phate (G-3-P) via multiple enzymatic steps (for a detailed 
review of PPP, see Riganti et al., 2012 and Patra and Hay, 
2014). Because F-6-P and G-3-P are also provided by the gly-
colytic process (Fig. 1), the NADPH from the oxidative phase 
is a unique biomolecule from PPP flux compared to glycolysis. 
The NADPH is essential for scavenging the reactive oxygen 
species (ROS) mainly derived from oxidative phosphorylation. 
In contrast, proliferating cells under nourished condition also 
have a high need for PPP activity to provide ribose-5-phos-
phate generating nucleotides and NADPH. The cancer cells 
in fast-life mainly consume NADPH during fatty acid synthesis 
(FAS) (Riganti et al., 2012). Thus, the regulatory network of 
PPP flux constitutes an important metabolic adaptation in vari-
ous environmental contexts in human cancer.
Fig. 1. The glycolysis and pentose phosphate pathways (PPP) are tightly connected. The glucose entering the in cell membrane is rapidly 
phosphorylated by HK and converted to G-6-P. The G-6-P is metabolized either by the glycolytic pathway, generating pyruvate and lactate, 
or by PPP to produce NADPH. The F-6-P and G-3-P generated from the non-oxidative branch of PPP can enter glycolysis or gluconeogen-
esis. The NADPH is generated from oxidative PPP in cytosolic space and serine-driven one carbon metabolism in mitochondria. Arrows 
indicate irreversible enzymatic steps, and bi-directional arrows indicate interconverting reversible reactions determined by substrate con-
centration. Inset (left) shows the feed-forward regulatory loop of PFK-1 as a rate-limiting step of glycolytic flux. G-6-P: glucose-6-phosphate, 
F-6-P: fructose-6-phosphate, F-1,6-P: fructose1,6-bisphosphate, F-2,6-BP: fructose2,6-bisphosphate, G-3-P: glyceraldehyde-3-phosphate, 
PEP: phosphoenolpyruvate, 6-PG: 6-phosphoglucolactone, R-5-P: Ribose-5-phosphate, HK: Hexokinase, PGI: phosphoglucose isomerase, 
PFK-1: phophofructokinase-1, FBP-1: fructose-1,6-bisphosphatase, PK: pyruvate kinase, G6PD: glucose-6-phosphate dehydrogenase, 
6-PGD: 6-phosphogluconate dehydrogenase, PFKFB: 6-phosphofructo-2-kiase/fructose-2,6-biphosphatase, TIGAR: TP53-induced glycoly-
sis and apoptosis regulator.
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PPP Is TIghTly cOnnecTeD TO glycOlysIs 
The glucose metabolism consists of highly interconnected 
pathways, and the key junctions between glycolysis and PPP 
being three important biomolecules: G-6-P, pyruvate, and ace-
tyl CoA. Upon entering cells, glucose is rapidly phosphory-
lated to G-6-P by hexokinase (HK), and is subsequently me-
tabolized toward glycolysis or the PPP. Although the PPP and 
glycolysis are divided from G-6-P, the metabolic circuit of both 
pathways is tightly connected, and a different flux mode is ac-
tive depending on metabolic demands. The reversible nature 
of enzymes through allosteric regulation in the non-oxidative 
branch enables the PPP to engage glycolysis to adapt to the 
metabolic demands of cells (Fig. 1). The R-5-P, a product of 
oxidative PPP, is converted into G-3-P and F-6-P by transketo-
lase (TKT) and transaldolase (TALDO1), creating a reversible 
metabolic link between PPP and glycolysis (Patra and Hay, 
2014). Diverse metabolic circuits between PPP and glycoly-
sis depend on the fundamental metabolic need for NADPH, 
R-5-P, and ATP (Berg et al., 2010) (Fig. 2). When rapidly pro-
liferating cells, such as cancer cells under nourished environ-
ment, require R-5-P rather than NADPH or ATP for the syn-
thesis of nucleotide precursors supporting a fast-life (Mode I), 
F-6-P and G-3-P produced from glycolysis can enter the PPP 
via TKT and TALDO1. In this process, 5 moles of G-6-P are 
converted to 6 moles of R-5-P by consuming ATP. When the 
G-6-P enters the PPP directly, two moles of NADPH and one 
of R-5-P are generated from 1 mole of G-6-P in oxidative PPP 
(Mode II). When the cell needs a high level of NADPH rather 
than R-5-P, the NADPH is efficiently produced by interplay be-
tween PPP and glycolysis (Mode III). In this flux mode, the first 
step is the same as Mode II, wherein 6 moles of G-6-P can 
generate 12 moles of NADPH and 6 moles of R-5-P. These 6 
moles of R-5-P are readily converted into 4 moles of F-6-P and 
2 moles of G-3-P by TKT and TALDO1, and 5 moles of G-6-P 
are synthesized from both F-6-P and G-3-P via the gluconeo-
genic pathway. This flux, also known as recycling PPP, can 
completely oxidize G-6-P to CO2 with concomitant generation 
of NADPH. Although the flux amount can hardly be quantified 
in cells, the recycling PPP mode might be very important in 
cells requiring a high NADPH level, such as liver, fat tissue 
and neuron (Bouzier-Sore and Bolanos, 2015). This recycling 
flux mode should utilize gluconeogenesis, a reverse reaction 
of glycolysis, and FBP1 which converts F-1,6-BP to F-6-P as 
a rate-limiting enzyme in this flux. Note that PFK-1 and FBP1 
interconvert F-6-P and F-1,6-P, representing rate-limiting bot-
Fig. 2. Diverse flux modes interconnecting glycolysis and PPP in different metabolic situations (modified from Berg et al., 2010). Major me-
tabolites are shown in red box and the stoichiometry of each mode is denoted. The PPP and glycolysis are reversibly linked by bi-directional 
transketolase (TKT) and transaldolase (TALDO1), as shown below.
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tlenecks of glycolysis and gluconeogenesis, respectively (dis-
cussed below in detail). Lastly, F-6-P and G-3-P derived from 
PPP can enter the glycolytic pathway to pyruvate (Mode IV). 
In this flux mode, NADPH and ATP are concomitantly gener-
ated, and the pyruvate can be oxidized to further generate 
ATP in mitochondria. Collectively, the PPP and glycolysis are 
tightly linked by bidirectional reactions of TKT and TALDO1, 
and the cancer cells utilize diverse flux modes depending on 
metabolic demand and the environmental situation.
MeTasTaTIc IneffIcIency DUrIng cancer 
PrOgressIOn
In nourished microenvironments, cancer cell proliferation is 
mediated via well-known aerobic glycolysis with an additional 
mitochondrial oxidative phosphorylation (Ox Phos) (Koppenol 
et al., 2011; Ward and Thompson, 2012). In this nourished 
condition, the cancer cell utilizes Mode I and Mode II of PPP 
flux, mainly to support anabolic metabolism. 
Distant metastasis comprises the most common cause of 
cancer mortality. It may therefore seem illogical to consider me-
tastasis as inefficient. Nevertheless, clinical and experimental 
evidence suggests that the metastatic progression of cancer 
cells is indeed highly inefficient (Tarin et al., 1984; Luzzi et al., 
1998; Chambers et al., 2002; Valastyan and Weinberg, 2011). 
Unlike hematopoietic cells, cancer cells arising from epithelial 
tissue (so-called carcinoma) should attach to the extracellular 
matrix, and matrix detachment leads to ATP deficiency and 
metabolic stress due to loss of glucose transport (Wong et 
al., 2001; Schafer et al., 2009). Conversely, matrix-detached 
and extravasated carcinoma cells must survive for success-
ful metastatic progression. To do so, the cancer cells essen-
tially require ATP, mainly derived from Ox Phos, NADH and 
NADPH, as a reducing power against oxidative stress (Cha 
et al., 2015). While oxidative phosphorylation mainly compen-
sates ATP depletion in starved cells, it concurrently generates 
intracellular ROS. Intracellular ROS are mainly produced from 
mitochondrial activity in complex I (NADH dehydrogenase) 
and complex III (ubiquinone-cytochrome c reductase) of the 
electron transporter chain (Finkel and Holbrook, 2000). Under 
resource-limited conditions, increased mitochondrial Ox Phos 
and increased levels of intracellular ROS inhibit fatty acid oxi-
dation (FAO) and ATP generation in a negative feedback loop 
(Riganti et al, 2012; Nogueira and Hay, 2013), impeding cell 
survival. A constant supply of reductive equivalents, specifi-
cally NADPH, for ROS detoxification is the key to maintaining 
metabolic homeostasis under stressful circumstances. Thus, 
cells under metabolic stressed condition, such as metastatic 
cancer cells, mainly use Modes III and IV flux of PPP to sup-
port catabolic metabolism. 
The IMPOrTance Of naDPh generaTIOn In 
cancer cells
NADPH is the major electron donor in the reductive meta-
bolic process. Although NADPH can be generated through 
several mechanisms, recent quantitative flux analysis indi-
cates that NADPH is mainly provided by cytosolic oxidative 
PPP and mitochondrial serine-driven one-carbon metabolism 
entering in folate-methionine cycles (Locasale, 2013; Fan et 
al., 2014) (Fig. 1). The serine is biosynthesized from G-3-P 
dervied either from PPP and glycolysis, and is catalyzed by 
3-phosphoglycerate dehydrogenase (PHGDH). Because the 
serine provides NADPH as well as amino acids, the impor-
tance of serine biosynthesis has recently emerged. Indeed, a 
small molecule inhibitor of PHGDH suppressed serine biosyn-
thesis and in vivo tumor growth in PHGDH-dependent cells 
(Mullarky et al., 2016; Pacold et al., 2016). While the serine 
derived from G-3-P generate 30-40% of NADPH under nour-
ished environment, it should be noted that FAS and DNA syn-
thesis in proliferating cells consume most of the NADPH (Fan 
et al., 2014). In starved condition with shutdown of glucose 
uptake, the role of serine-driven NADPH biosynthesis and 
ATP generation is still unclear and further study is required in 
terms of cell survival during cancer progression. In this review, 
we mainly focus on flux control towards PPP by environmental 
cues and ongogenic mutation in cancer cells. 
glUcOse flUx cOnTrOl beTween The PPP anD 
glycOlysIs In cancer
The glucose entering the PPP may vary from 5-30%, de-
pending on tissue (Riganti et al., 2012). With enough glu-
cose in non-dividing cells under normal physiologic condition, 
NADPH is mostly consumed during FAS. Therefore, high PPP 
flux is reached in liver, adipose tissue, lactating mammary 
glands, adrenal glands, and red blood cells (Cabezas et al., 
1999; Riganti et al., 2012). The basal rate of the PPP, a major 
source of NADPH, mainly depends on the NADP+/NADPH ra-
tio; moreover, the G6PD enzyme is highly specific for NADP+. 
Recently, metabolic regulation of PPP flux in human disease 
has gained significant attention due to the metabolic path-
way’s function against oxidative stress. 
As noted earlier, matrix detachment of solid tumor cells in-
duces ATP deficiency accompanied by increased ROS level 
due to the loss of glucose uptake. In this metabolic stress 
condition, the ERBB2 oncogene rescues the ATP depletion 
depending on glucose flux into PPP (Schafer et al., 2009) al-
though the mechanistic link between ERBB2 and PPP is still 
unclear. There are several regulatory mechanisms involved 
in the flux control between glycolysis and PPP, including re-
ciprocal interactions. First, PPP flux can be controlled by the 
glycolytic pathway. When the glycolytic pathway is inhibited, 
glucose re-flux towards the PPP is increased. Second, phos-
phofructokinase-1 (PFK-1) and pyruvate kinase (PK) convert 
irreversible enzymatic steps in glycolytic reactions. These en-
zymatic steps serve as important control sites of glycolytic flux 
via reversible allosteric control, post-translational modification 
(such as phosphorylation and O-glycosylation), and transcrip-
tional regulation (Fig. 3). Therefore, genetic alterations in can-
cer and metabolic cues controlling glucose flux between PPP 
and glycolysis involve enzymatic steps catalyzed by (1) G6PD 
as a gatekeeper of PPP flux, and (2) PFK-1 and PK as a rate-
limiting step of glycolysis (Fig. 3). 
PfK-1 anD PK cOnTrOl flUx beTween The PPP 
anD glycOlysIs In cancer 
PFK-1 is the most important control site in mammalian gly-
colysis as a first rate-limiting step, the kinase activity being in-
Biomol  Ther 26(1),  29-38 (2018)
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hibited by ATP level in a negative feedback loop. Compared to 
G6PD and PK, the regulatory mechanism of PFK-1 is complex 
due to the presence of fructose 2,6-bisphosphate (F-2,6-BP), 
which forms in a reaction catalyzed by PFK-2, which acts as 
a potent activator of PFK-1 by increasing the affinity of PFK-1 
to F-6-P and decreasing the inhibitory effect of ATP (Fig. 3). 
PFK-2 is a bi-functional enzyme that catalyzes the synthesis 
of F-2,6-BP from F-6-P with the N-terminal kinase domain and 
also catalyzes the reverse hydrolysis reaction with the C-ter-
minal phosphatase domain (for a review of PFK-2, see Ros 
and Schulze, 2013). There are several PFK-2 isoenzymes in 
mammals, PFKFB1 to PFKFB4. Increased levels of F-2,6-BP 
allow cancer cells to maintain a high glycolytic activity inde-
pendent of ATP levels (Berg et al, 2010). Therefore, F-2,6-
BP level can be controlled by pharmacologic inhibition of N-
terminal kinase activity on PFKBPs. Indeed, a small molecule 
inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-
1-one (3PO), suppressed glycolytic metabolites such as lac-
tate, ATP, and NADH while also attenuating the proliferation 
of cancer cells (Clem et al., 2008); the effect of 3PO on PPP 
flux is not yet known. Interestingly, PFKFB4 was identified as 
a therapeutic target of cancer, especially in prostate cancer 
(Ros et al., 2012). Knockdown of PFKFB4 leads to a signifi-
cant increase in F-2,6-BP in cancer cells followed by decreas-
ing NADPH level and increasing ROS with cancer cell death. 
As a well-known tumor suppressor in human cancer, p53 is 
involved in PFK-1 activity via transcriptional upregulation of 
TIGAR (TP53-induced glycolysis and apoptosis regulator) 
(Bensaad et al., 2006). Because the TIGAR possesses only 
the bisphosphatase active site lacking N-terminal kinase do-
main of PFKFB, it degrades F-2,6-BP cellular levels and thus 
inhibits PFK-1 activity and glycolysis (Li and Jogl, 2009; Mor 
et al., 2011). The inhibition of glycolysis by TIGAR increases 
PPP flux and NADPH levels with enhanced ability to regulate 
cellular ROS level and oxidative stress (Bensaad et al., 2006; 
Cheung et al., 2012; Ko et al., 2016). While the role of TIGAR 
in PPP flux is clear, it should be noted that p53 is involved in 
various levels of metabolic PPP circuitry other than TIGAR (for 
the effect of p53 on metabolism, see Kruiswijk et al., 2015).
As a gate-keeper of glycolysis, the PFK-1 constitutes an 
important control step regulating glucose flux between PPP 
and glycolysis. PFK-1 in mammal is encoded by three genes: 
Fig. 3. Oncogenic regulation of glucose flux into PPP. 
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PFKL and PFKM, expressed in liver and muscle respectively, 
and PFKP, mainly expressed in platelet, each encoding a dif-
ferent isoform. In human cancer, the PFKP isoform prevails 
over PFKM or PFKL and is a major controlling step of aerobic 
glycolysis in human cancer (Kim et al., 2017). Post-transla-
tional O-GlcNAcylation on Ser residue of PFK-1 in response 
to hypoxia inhibits its kinase activity and redirects glucose flux 
towards the PPP, conferring a selective advantage against 
oxidative stress on cancer cells (Yi et al., 2012). Recently, 
cyclin D3-CDK6 complex has been found to phosphorylate 
and inhibit the PFKP in cancer (Wang et al., 2017). This in-
hibition of PFKP by CDK6 also redirects glucose flux into the 
PPP, providing a pro-survival function under metabolic stress. 
Snail, a key regulator of cancer EMT, suppresses glycolysis 
by transcriptional repression of PFKP and regulates glucose 
flux toward PPP, allowing cancer cell survival under metabolic 
stress condition similarly to CDK6 (Kim et al., 2017). Knock-
down of PFKP significantly suppressed glycolytic flux with G0/
G1 cell cycle arrest and ceased cell proliferation. However, 
suppression of PFKP significantly increased cancer cell sur-
vival under metabolic starved condition by increasing PPP flux 
and NADPH generation. Cancer cells in which endogenous 
PFKP was dynamically knockdowned exhibited increases 
resistance to oxidative stress as well as metastatic potential 
in vivo (Kim et al., 2017). Thus, suppression of PFKP during 
EMT provides cell survival advantage via Mode III flux. Note 
that FBP1, which catalyzes the reverse reaction of PFKP and 
constitutes a gatekeeper of gluconeogenesis, is also down-
regulated in many types of human cancer (Dong et al., 2013; 
Li et al., 2014; Zhang et al., 2016). Interestingly, Snail or ZEB1 
EMT inducer also suppresses FBP1 expression, and restor-
ing FBP1 in cancer cells inhibits invasion and tumorigenic po-
tential. Paradoxically, loss of FBP1 decreases cellular ROS 
level similarly to suppression of FPKP. Although whether and 
how FBP1 controls flux into PPP remains unclear, the loss 
of FBP1 in cancer allows high glycolytic flux under nourished 
environment and may provide survival advantage with Mode 
IV flux under starved condition by generating NADPH and ATP 
together. Therefore, as rate-limiting steps of glycolysis and 
gluconeogenesis, the bidirectional suppression of PFKP and 
FBP1 by Snail repressor may play important role in regulating 
flux control in response to metabolic demands of cancer cells. 
PK, the enzyme catalyzing the last irreversible step in 
glycolysis, also controls the glucose flux of glycolysis. In 
mammals, several isoforms of PK are encoded by different 
genes: L type in liver and the M type in muscle and brain. In 
human cancer, the M2 isoform of PK (PKM2) is exclusively 
expressed similarly to PFKP, and the PKM2 is phosphorylated 
by tyrosine kinase, resulting in inhibition of PKM2 kinase activ-
ity (Christofk et al., 2008a, 2008b). Interestingly, intracellular 
ROS and CDK6 directly inhibit PKM2 activity via oxidation and 
phosphorylation, respectively (Anastasiou et al., 2011; Wang 
et al., 2017). The inhibition of PKM2 by ROS or CDK6 sup-
presses glycolytic flux together with increased PPP flux and 
NADPH generation, providing a survival advantage to cancer 
cells (Fig. 3). 
g6PD Is a PPP flUx cOnTrOller In cancer 
The PPP comprises two phases: the oxidative and the non-
oxidative branches. Glucose-6-phosphate dehydrogenase 
(G6PD) generates NADPH in the oxidative PPP by oxidizing 
G-6-P to 6-phosphogluconolacton (6-PG). A second NADPH 
and CO2 are generated downstream via oxidative decarbox-
ylation of 6-phosphogluconic acid by 6-phosphogluconic de-
hydrogenase (6PGD), the last step of the oxidative branch 
producing ribulose/ribose-5-phosphate (R-5-P) (Riganti et al., 
2012; Stanton, 2012). The nonoxidatvie branch comprises 
a series of reversible reactions by the allosteric enzymes to 
adapt to the metabolic demands of cells. As noted earlier, 
F-6-P and G-3-P can pass in either direction between the 
nonoxidative PPP branch and the glycolytic pathway (Fig. 1). 
Therefore, G6PD is the first committed enzyme for NADPH 
generation in the oxidative PPP branch; we only focus on the 
PPP oxidative branch, which maintains the redox balance in 
cancer cells. 
Not surprisingly, cancer cells exhibit higher expression of 
G6PD than normal tissue (Bokun et al., 1987; Wang, Yuan 
et al. 2012). Several oncogenic signals are associated with 
PPP flux regulation through G6PD. The cytoplasmic p53 tu-
mor suppressor directly interacts with G6PD and inhibits its 
activity, resulting in a decreasing both PPP flux and NADPH 
generation (Jiang et al., 2011). This observation merits special 
attention in terms of the role of p53 on PPP flux because p53’s 
downstream target TIGAR increased the PPP flux, as noted 
earlier (Bensaad et al., 2006; Li and Jogl, 2009; Mor et al., 
2011). The p53 also suppresses Snail via post-transcriptional 
regulation of miRNA-34 (Kim et al., 2011). Therefore, the role 
of p53 tumor suppressor and its downstream targets in hu-
man cancer require further study in terms of metabolic flux into 
glycolysis and PPP. Another member of the p53 family, p73, 
increases PPP flux and NADPH production via transcriptional 
activation of G6PD (Du et al., 2013). An earlier study revealed 
that epidermal growth factor (EGF) or platelet-derived growth 
factor (PDGF) increase G6PD activity, while the mechanistic 
link between receptor tyrosine kinase and G6PD is not well 
understood (Stanton et al., 1991). These observations indi-
cate that G6PD is a key controller of PPP flux regulated by 
many oncogenes, and further investigation is required into 
G6PD regulation by oncogenes providing proliferation and 
survival advantage of cancer cells. 
g6PD as a TheraPeUTIc TargeT In cancer 
cells 
Emerging evidence suggests that G6PD, a gatekeeper of 
PPP, is a potential therapeutic target of human cancer. Prior to 
discussing it as a cancer target, we should note the extensive 
epidemiological background of G6PD deficiency, the most 
common human genetic alteration, which has been studied 
for the past 90 years.
The PPP was first described in the 1920s, when the in-
troduction of new antimalarial drugs such as primaquine led 
to drug-induced hemolytic anemia (cited from Riganti et al., 
2012). Subsequently, it was revealed that individuals with 
primaquine-sensitive hemolysis and lowered reduced-form of 
GSH were G6PD-deficient (Carson et al., 1956). In red blood 
cells lacking mitochondria as well as nucleus, the PPP is the 
exclusive route for NADPH production. Therefore, attenuated 
PPP due to G6PD deficiency renders red blood cells more 
vulnerable to drug-induced oxidative stress. G6PD-encoding 
genes map at the telomeric region of the distal long arm of 
Biomol  Ther 26(1),  29-38 (2018)
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the X chromosome (Xq28 locus). G6PD deficiency is the 
most common genetic mutation in the world, estimated to oc-
cur in at least 400 million people worldwide (Nkhoma et al., 
2009). WHO has classified about 300 variants into several 
classes according to mutant enzymatic activity. Most G6PD 
deficiencies are class II, having less than 10% activity com-
pared to wild type, although the majority of individuals remain 
asymptomatic until they are exposed to certain drugs (Stan-
ton, 2012). These suggest that mitochondrial one-carbon me-
tabolism may compensate NADPH during the developmental 
process and normal life although the contribution of the one-
carbon metabolism to NADPH homeostasis in G6PD-deficient 
individuals is still unknown. 
Due to the pivotal role of G6PD in PPP flux and cellular 
redox balance, there is an interesting epidemiological hypoth-
esis that G6PD deficiency is inversely correlated to cancer 
incidence and mortality. While lower cancer prevalence in 
G6PD-deficient individuals was reported from a large epide-
miological study conducted in 1980s, the results were incon-
clusive (Cocco et al., 1987). Cancer mortality from all cancer 
was lower in G6PD-deficient individuals compared to wild-type 
phenotype (Cocco et al., 1996). Recently, a large reduction in 
colorectal cancer risk among G6PD-deficient individuals was 
reported in a long-term cohort study of sub-Saharian Africa 
(Dore et al., 2016). 
This epidemiological evidence provides important insights 
for a G6PD therapeutic stategy for human cancer. First, G6PD 
abundance is increased in many types of human cancer. Fur-
thermore, active oxidative PPP is observed in tumors with mul-
tidrug resistance in preexisting chemotherapeutics (Riganti et 
al., 2012). Thus, PPP inhibition may serve as a therapeutic 
target based on the lower risk of cancer in the G6PD-deficient 
population. Second, most asymptomatic G6PD-deficient indi-
viduals have less than 10% enzymatic activity compared to 
wild type G6PD. In experimental settings, embryonic stem 
cells with complete G6PD deletion proliferate normally but are 
susceptible to oxidative stress (Pandolfi et al., 1995; Paglial-
unga et al., 2004). These observations suggest an interesting 
aspect of PPP inhibition in that a specific inhibitor of G6PD 
or 6-PGD can be less toxic in normal cells compared to con-
ventional cytotoxic therapeutics. Indeed, a specific inhibitor 
of 6-PGD effectively attenuates tumor growth in vivo without 
obvious toxicity (Lin et al., 2015). However, PPP inhibition 
alone has limited therapeutic potential because it inevitably 
increases NADP+, a potent activator of G6PD. There are many 
G6PD inhibitors (Singh et al., 2012; Preuss et al., 2013), one 
of interest being dehydroepiandrosterone (DHEA). DHEA is 
one of the most abundant circulating endogenous steroids 
in human, produced from the adrenal gland and gonads dur-
ing cholesterol metabolism. As an uncompetitive inhibitor of 
G6PD, DHEA is also used orally as a dietary supplement (Fig. 
4A) (Gordon et al., 1995). DHEA has very low toxicity in hu-
man, daily doses up to 1.6 g taken orally for one month be-
ing well tolerated. As mentioned earlier, the Snail/PFKP axis 
increased PPP flux and NADPH levels in a G6PD-dependent 
manner and DHEA treatment reversed NADPH homeostasis 
induced by Snail repressor (Fig. 4B). Since the suppression of 
PFKP leads to PPP reflux, dynamic knockdown of PFKP sig-
nificantly increases cancer cell survival under glucose starved 
condition and DHEA largely attenuates breast cancer cell sur-
vival as determined by clonogenic capacity (Fig. 4C). The anti-
oxidative capacity is also closely related to chemotherapeu-
tic resistance to paclitaxel, one of the most commonly used 
therapeutics for human cancer (Ramanathan et al., 2005). 
Indeed, DHEA enhances the therapeutic potential of paclitaxel 
on MDA-MB-231 breast cancer cells (Fig. 4D). While DHEA 
clearly inhibits PPP flux and NADPH production in vitro (Tian 
et al., 1998; Schafer et al., 2009), its anti-cancer effect in vivo 
has not been thoroughly studied. Note that lowered ROS lev-
els are critically required for radioresistance in cancer stem 
cells (Diehn et al., 2009); however, the role of PPP in radia-
tion-induced cancer cell death is also needs further research.
Based on epidemiological evidence of G6PD deficiency and 
metabolic charateristics of PPP in human cancer, we propose 
G6PD as a potential target of a synthetic lethal therapeutic 
approach for human cancer combined with coventional cyto-
toxic or targeted therapeutics. Other metabolic targets, such 
as aldehyde dehydrogenase (ALDH), mitochondrial metabo-
lism, glutamine metabolism and fatty acid oxidation, also hold 
promise for use in combinatory theraputics to inhibit G6PD in 
cancer (Kim, 2015). Further study of oncongenic function on 
PPP flux and for development of specific inhibitor of G6PD 
might provide new insights to clinical benefit of cancer treat-
ment.
Fig. 4. The DHEA, an uncompetitive inhibitor of G6PD, regulated NADPH level and cancer cell survival under metabolic stress. (A) Chemi-
cal structure of DHEA. (B) Snail increased NADPH levels and siRNA-mediated or DHEA treatment reverted anti-oxidant level in MCF-7 
and MDA-MB-231 cells. (C) Clonogenic survival assay of cancer cells following glucose starvation for 72 h. Knockdown of PFKP increased 
cell survival under glucose starvation and DHEA (20 μg/ml) treatment reversed the effects of PFKP knockdown. (D) Clonogenic survival of 
MDA-MB-231 cells against paclitaxel treatment as indicated by concentration. The DHEA and paclitaxel were treated for a 48 h period, and 
clonogenic capacity was determined. Statistical significances compared with each control are denoted as **p<0.01. See Kim et al. (2017) 
for the experimental procedures for NADPH and clononogenic assay.
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cOnclUsIOns
Cancer cells adapt their metabolic circuitry to support pro-
liferation under nourished fast-life as well as to survive un-
der starved slow-life. Emerging evidence suggests that PPP 
flux is increased in human cancer and that the PPP plays an 
important role in cancer progression although the oncogenic 
regulation of PPP is not fully understood yet. During the natu-
ral history of cancer initiation and progression, cancer cells 
are inevitably and repeatedly exposed to a metabolic starved 
environment. Under starved condition, the ATP and NADPH 
are essential to the slow-life of cancer cells. The ATP is gener-
ated by the oxidation (mainly from oxidative phosphorylation 
in mitochondria) of many molecules such as glucose, fatty ac-
ids, and amino acids. NADPH mainly generated from PPP is 
the major electron donor in reductive biosynthesis supporting 
the oxidation process. As discussed earlier, cancer cells have 
acquired mechanisms to activate PPP based on metabolic de-
mand. Further studies will uncover additional mechanisms by 
which cancer cells utilize the PPP to support their survival and 
proliferation. Also, more work is needed to find a novel and 
specific therapeutics for hyperactive PPP in human cancer. 
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